Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Status:
Terminated
Trial end date:
2019-03-11
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomized phase 2 study to assess overall response rate (ORR),
clinical benefit rate (CBR), overall survival (OS) and progression free survival (PFS) in
patients with high grade neuroendocrine tumors treated with pembrolizumab 200mg Q 3 Weeks.